Serrano-Snchez V, Ripolls-de Ramn J, Collado-Yurrita L, Vaello-Checa I, Colmenero-Ruiz C, Helm A, Ciudad-Cabaas MJ, Serrano-Cuenca V. New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery. Med Oral Patol Oral Cir Bucal. 2017 Sep 1;22 (5):e601-8.  

 

 

doi:10.4317/medoral.21862

http://dx.doi.org/doi:10.4317/medoral.21862

 

 

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370-5.
https://doi.org/10.1001/jama.285.18.2370

 

2. Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746-51.
https://doi.org/10.1093/eurheartj/eht280

 

3. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. The Oxford University Press. 2014;16:965-72.

 

4. Imberti D, Gallerani M, Manfredini R. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J Thromb Thrombolys. 2012;34:208-13.
https://doi.org/10.1007/s11239-012-0716-8

 

5. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431-41.
https://doi.org/10.1016/j.oooo.2011.10.005

 

6. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010;113:726-45.
https://doi.org/10.1097/ALN.0b013e3181ebdb15

 

7. Ezekowitz MD, Connolly SJ, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-10.
https://doi.org/10.1016/j.ahj.2009.02.005

 

8. Conolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabiagtran versus Warfarin in patients with Atrial Fibrillation. N Engl J Med. 2009;361:1139-51.
https://doi.org/10.1056/NEJMoa0905561

 

9. ROCKET AF Study Investigators. Rivaroxaban — once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340 .e1-347. e1.

 

10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365:883-91.
https://doi.org/10.1056/NEJMoa1009638

 

11. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibril- lation. N Engl J Med. 2011;364:806-17.
https://doi.org/10.1056/NEJMoa1007432

 

12. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD et al. Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-9.
https://doi.org/10.1016/j.ahj.2009.07.035

 

13. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in patients with Atrial Fibrillation. N Eng J Med. 2011;365:981-92.
https://doi.org/10.1056/NEJMoa1107039

 

14. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev. 2013;2:358-66.
https://doi.org/10.1002/cpdd.53

 

15. Ruff CT, Giugliano RP, Antman EM, Crugnale Se, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-41.
https://doi.org/10.1016/j.ahj.2010.06.042

 

16. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Eng J Med. 2013;269:2093-104.
https://doi.org/10.1056/NEJMoa1310907

 

17. Arcelus JI, Cairols M, Granero X, Jimnez D, Llau JV, Monreal M, et al. Nuevos anticoagulantes orales: una visin multidisciplinaria. Med Clin (Barc). 2009;133:508-12.
https://doi.org/10.1016/j.medcli.2009.03.027

 

18. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants inpatients with non-valvular atrial fibrillation. Europace. 2013;15:625-51.
https://doi.org/10.1093/europace/eut083

 

19. Weitz JI, Pollack CV Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015;114:1113-26.
https://doi.org/10.1160/TH15-03-0222

 

20. Wysokinski WE, McBaneR D. Periprocedural bridging management of anticoagulation. Circulation. 2012;126:486-90.
https://doi.org/10.1161/CIRCULATIONAHA.112.092833

 

21. Du S, Weiss C, Christina G, Krmer S, Wehling M, Krmer R, et al. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods. Clin Chem Lab Med. 2015;53:1237-47.
https://doi.org/10.1515/cclm-2014-0991

 

22. Harenberg J, Du S, Wehling M, Zolfaghari S, Weiss C, Krmer R, et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med. 2016;54:275-83.
https://doi.org/10.1515/cclm-2015-0389

 

23. Barrios V, Caldern A, Escobar C, De la Figuera M. Pacientes con fibrilacin auricular asistidos en consultas de atencin primaria. Estudio Val-FAAP. Rev Esp Cardiol. 2012;65:47-53.
https://doi.org/10.1016/j.recesp.2011.08.008

 

24. Chao T, Lin YJ, Tsao HM, Tsai CF, Lin WS, Chang SL, et al. CHADS2 and CHA2DS2-VASc Scores in the Prediction of Clinical Outcomes in Patients With Atrial Fibrillation After Catheter Ablation. J Am Coll Cardiol. 2011;58:2380-5.
https://doi.org/10.1016/j.jacc.2011.08.045

 

25. Pisters R, Lane DA, Nieuwlaat R, De Vos RNC, Crijns HJG, Lip GYH. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest. 2010;138:1093-100.
https://doi.org/10.1378/chest.10-0134

 

26. Ment J. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial brillation. Vasc Health Risk Manag. 2015;11:317-32.
https://doi.org/10.2147/VHRM.S79065

 

27. Ebright J, Mousa SA. Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Thromb Hemost. 2015;21:105-14.
https://doi.org/10.1177/1076029614545211

 

28. Liotta EM, Levasseur-Franklin KE, Naidech AM. Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. Curr Opin Crit Care. 2015;21:127-33.
https://doi.org/10.1097/MCC.0000000000000181

 

29. Constantinides F, Rizzo R, Pascazio L, Maglione M. Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. Oral Health. 2016;16:5.
https://doi.org/10.1186/s12903-016-0170-7

 

30. Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Diseases. 2016;22:23-32.
https://doi.org/10.1111/odi.12371

 

31. Gonzlez Fernndez-Tresguerres F, lvarez Sirvent A, Torres Garca-Denche J, Fernndez-Tresguerres Hernndez-Gil I. Nuevos anticoagulantes orales: repercusin odontolgica. Cient Dent. 2016;13;2:139-48.

 

32. Mauprivez C, Khonsari R, Razouk O, Goudot P, Lesclous P, Descroix V. Management of dental extraction in patients undergoing anticoagulant oral direct treatment. A pilot study, Oral Surg Oral Med Oral Pathol Oral Radiol. 2016. En prensa.

 

33. Hong CH, Islam I. AntiThrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry. J Blood Disorders Transf. 2013;4:166.
https://doi.org/10.4172/2155-9864.1000166

 

34. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014;14:147-54.
https://doi.org/10.1007/s40256-013-0055-y

 

35. Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol. 2015;35:1736-45.
https://doi.org/10.1161/ATVBAHA.114.303402

 

36. Weitz JI, Pollack CV Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015;114:1113-26.
https://doi.org/10.1160/TH15-03-0222

 

37. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-31.
https://doi.org/10.1111/j.1538-7836.2008.02904.x

 

38. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35-44.